8-K
filed January 31, 2023, 6:59 PM ET
ticker EW
CIK 0001099800
earnings
confidence high
sentiment neutral
materiality 0.80
Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64
Edwards Lifesciences Corp
2022-FY EPS reported
$2.44
revenue$5,382,400,000
- Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.
- Full-year 2022 sales $5.38B (+3%); adjusted EPS $2.48 (+12% YoY).
- Repurchased $1.7B of stock in 2022; $900M remaining under authorization.
- Q4 adjusted gross margin improved to 81.0% from 76.8% a year ago.
- Reiterated 2023 outlook: sales growth 9-12% ($5.6-$6.0B); adjusted EPS $2.45-$2.60.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Edwards Lifesciences Corp reported quarter ended December 31, 2022 results: revenue $1.35 billion, EPS $0.65.
- Period
- quarter ended December 31, 2022
- Revenue
- $1.35 billion
- EPS
- $0.65
- Result
- reported results
Exact text from the filing
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook • Q4 sales grew 1 percent to $1.35 billion; constant currency 1 sales grew 7 percent • Q4 TAVR sales were flat; constant currency sales grew 5 percent • Q4 EPS of $0.65; adjusted 1 EPS increased 25 percent to $0.64
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Edwards Lifesciences Corp reported first quarter of 2023 results: revenue $1.37 to $1.45 billion, EPS $0.58 to $0.64. Guidance initiated.
- Period
- first quarter of 2023
- Revenue
- $1.37 to $1.45 billion
- EPS
- $0.58 to $0.64
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Edwards Lifesciences Corp reported full year 2023 results: revenue $5.6 to $6.0 billion, EPS $2.45 to $2.60. Guidance reaffirmed.
- Period
- full year 2023
- Revenue
- $5.6 to $6.0 billion
- EPS
- $2.45 to $2.60
- Guidance
- reaffirmed
- Result
- guidance update
Exact text from the filing
Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Edwards Lifesciences Corp reported year ended December 31, 2022 results: revenue $5.38 billion, EPS $2.44.
- Period
- year ended December 31, 2022
- Revenue
- $5.38 billion
- EPS
- $2.44
- Result
- reported results
Exact text from the filing
Sales for the year ended December 31, 2022, were $5.38 billion, a year-over-year increase of 3 percent, or 8 percent on an underlying basis. Although initial sales expectations for 2022 anticipated a better healthcare environment, the company delivered balanced contributions across each of its product groups and regions. Diluted earnings per share for 2022 were $2.44, while adjusted earnings per share of $2.48 increased 12 percent from the year-ago period.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.